Patents by Inventor Iris LAVON BEN MOSHE

Iris LAVON BEN MOSHE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment for glioblastoma
    Patent number: 11478453
    Abstract: The invention relates to the treatment of brain tumors, specifically to improved therapy for glioblastoma utilizing specific endocrine modulators and drug combinations. The compositions and uses thereof according to the invention employ androgen receptor (AR) inhibitors, either alone or in combination with receptor tyrosine kinase inhibitors and/or chemotherapeutic agents. According to certain advantageous embodiments, the use of the AR inhibitor enzalutamide, optionally in combination with epidermal growth factor receptor inhibitors such as erlotinib and alkylating agents such as carmustine and temozolomide, is contemplated.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: October 25, 2022
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Iris Lavon Ben Moshe, Tamar Canello Avramovitch
  • MARKERS OF DISEASE PROGNOSIS IN MULTIPLE SCLEROSIS
    Publication number: 20220049309
    Abstract: Provided are methods and kits for early determination of disease outcome and prognosis of Multiple Sclerosis (MS) patients and for adjustment of suitable treatment.
    Type: Application
    Filed: December 11, 2019
    Publication date: February 17, 2022
    Inventors: Adi Vaknin-Dembinsky, Iris Lavon Ben Moshe
  • TREATMENT FOR GLIOBLASTOMA
    Publication number: 20190240199
    Abstract: The invention relates to the treatment of brain tumors, specifically to improved therapy for glioblastoma utilizing specific endocrine modulators and drug combinations. The compositions and uses thereof according to the invention employ androgen receptor (AR) inhibitors, either alone or in combination with receptor tyrosine kinase inhibitors and/or chemotherapeutic agents. According to certain advantageous embodiments, the use of the AR inhibitor enzalutamide, optionally in combination with epidermal growth factor receptor inhibitors such as erlotinib and alkylating agents such as carmustine and temozolomide, is contemplated.
    Type: Application
    Filed: July 20, 2017
    Publication date: August 8, 2019
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Iris LAVON BEN MOSHE, Tamar CANELLO AVRAMOVITCH